Biotest Ag

Other

Biodics

Jochem, Ralf

Veit Braun

Dieter Rudnick

Matthias Germer

Oliver Maneg

Michael Rodemer

Wolfgang Möller

Christoph Von Eichel-Streiber

Franz Paul Armbruster

Wolfgang Moeller

Michael Moos

Herbert Dichtelmueller

Eckhard Flechsig

Christoph Von Eichelstreiber

Karina Gisch

Ralf Jochem

An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.

Methods of treating viral infections by administering an antibody preparation comprising IGG, IGA and IGM

IgG, IgA and IgM antibody preparations, method of making and method of use in treatment

An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5 % IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.

Antibody preparations

The method for detecting and identifying a variantstrain in a sample is characterized by the following steps: (a) obtaining a sample of excreta or tissue from a human or animal patient body; (b) bringing the sample into contact with at least one antibody from each of at least three of the antibody groups group I, group II, group III, group IV, group V and group VI; (c) detecting the antibody reaction and constructing the reaction pattern; (d) comparing the reaction pattern obtained in (c) with reference patterns from knownstrains andstrains the presence of which is to be tested in the investigation test; (e) assessing the agreement between the reaction pattern obtained in (c) and the reference pattern as indicative of the presence of thestrain of the reference pattern concerned in the sample.

[object Object]

The invention is relates to drugs on the basis of antibodies against non-cellular bone matrix proteins, especially BSP, for use in the prevention and treatment of bone metastases. According to the invention, the antibodies are induced in the patient by recombinantly expressing antigenic determinants of bone matrix proteins inand anchoring them on the surfaces thereof. The antigenic determinants are selected according to whether they are characteristic of antigens that are expressed by the tumor cells themselves.

Therapeutic composition for use in the prevention and treatment of bone metastases

Growing community of inventors

Mainz, Germany

Veit Braun